AV-203 is under clinical development by AVEO Pharmaceuticals and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I drugs for Bladder Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AV-203’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AV-203 overview
AV-203 is under development for the treatment of metastatic or advanced solid tumor including, squamous non-small cell lung cancer, lung adenocarcinoma, colorectal tumor, skin cancer, ovarian cancer, peritoneal tumor, small-cell lung cancer, endometrial cancer, osteosarcoma, metastatic hepatocellular carcinoma (HCC), pancreatic tumor, breast cancer, neuroendocrine tumors, bladder cancer, mesothelioma, head and neck cancer squamous cell carcinoma, and cervical cancer. The drug candidate is administered intravenously through infusion. It is a selective anti-ErbB3 antibody. ErbB3 is a type 1 tyrosine kinase receptor of the EFGR family that is widely expressed in human carcinomas. It has been developed through the use of a technology platform known as the human response platform.
It was also under development for the treatment of esophageal squamous cell carcinoma.
AVEO Pharmaceuticals overview
AVEO Pharmaceuticals (AVEO), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products in the pipeline. The company develops products through strategic partnerships with other pharmaceutical companies. AVEO is headquartered in Boston, Massachusetts, the US.
For a complete picture of AV-203’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
